SS Innovations International (NASDAQ:SSII) and AtriCure (NASDAQ:ATRC) Financial Analysis
by Danessa Lincoln · The Markets DailySS Innovations International (NASDAQ:SSII – Get Free Report) and AtriCure (NASDAQ:ATRC – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Valuation and Earnings
This table compares SS Innovations International and AtriCure”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SS Innovations International | $42.49 million | 6.37 | -$12.13 million | ($0.06) | -22.50 |
| AtriCure | $534.53 million | 5.27 | -$11.45 million | $0.30 | 184.37 |
AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SS Innovations International and AtriCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SS Innovations International | -23.73% | -26.77% | -15.01% |
| AtriCure | 2.52% | 4.01% | 3.03% |
Analyst Recommendations
This is a summary of current recommendations and price targets for SS Innovations International and AtriCure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SS Innovations International | 1 | 0 | 0 | 0 | 1.00 |
| AtriCure | 1 | 4 | 6 | 1 | 2.58 |
SS Innovations International currently has a consensus price target of $7.00, suggesting a potential upside of 418.52%. AtriCure has a consensus price target of $62.30, suggesting a potential upside of 12.64%. Given SS Innovations International’s higher probable upside, equities analysts clearly believe SS Innovations International is more favorable than AtriCure.
Risk & Volatility
SS Innovations International has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Insider & Institutional Ownership
99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
AtriCure beats SS Innovations International on 12 of the 14 factors compared between the two stocks.
About SS Innovations International
SS Innovations International is a medical technology company focused on developing and manufacturing surgical robotic systems. Its flagship product, the SSI Mantra, is a multi-arm platform designed to support surgeons during minimally invasive procedures. The company’s offerings include surgical instruments and related technologies, such as its SSI Mudra instruments, as well as training and support services for hospitals and clinicians. The SSI Mantra system is designed with features including a surgeon console and 3D visualization, and the company has also emphasized remote surgery and telementoring capabilities.
About AtriCure
AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.